Neil Ku­mar’s Bridge­Bio team locks in a $2.4B part­ner­ship as their next drug gets a snap re­view at the FDA

5 years ago
Deals

How Biden’s in­fra­struc­ture plan will go af­ter bio­phar­ma com­pa­nies be­yond drug pric­ing

5 years ago
Pharma

Af­ter leav­ing Mer­ck­'s C-suite, Mike Nal­ly turns up at the helm of a Flag­ship ma­chine learn­ing com­pa­ny

5 years ago
People

Look­ing to crack down on big bio­phar­ma M&A deals, FTC sues to block Il­lu­mi­na's $8B Grail ac­qui­si­tion

5 years ago
Deals
FDA+

Am­gen takes a swing at re­gen­er­a­tive im­munol­o­gy with $721M ac­qui­si­tion of Rodeo Ther­a­peu­tics

5 years ago
Deals

Re­call re­port: Zy­dus re­calls her­pes drug af­ter crys­tal­liza­tion com­plaints; Alem­bic pulls low blood pres­sure drug for ...

5 years ago
Manufacturing

In­tel­lia an­nounced a new tool for gene edit­ing. Aca­d­e­mics said they rewrote his­to­ry

5 years ago
Discovery

House Dems seek to over­turn Trump-era rule that could gut FDA’s reg­u­la­tions

5 years ago
Pharma
FDA+

Mer­ck lines up a buy­out deal for soon-to-be wom­en's health spin­out

5 years ago
Deals

Armed with Pfiz­er's ADC plat­form, Pyx­is scores $152M round to shoot for the clin­ic while tak­ing its time on I/O ...

5 years ago
Financing

For­ma sees da­ta 'sup­port­ing' sick­le cell ther­a­py dos­ing lev­els; Lian­Bio teams with Tar­sus for eye ir­ri­ta­tion in Chi­na

5 years ago
News Briefing

HHS reg­u­la­to­ry agen­da for 2021 is light on new pro­posed and fi­nal FDA rules

5 years ago
Pharma
FDA+

Af­ter dis­miss­ing CFO over 'i­nap­pro­pri­ate mes­sages,' Eli Lil­ly faces new ac­cu­sa­tions of sex­u­al dis­crim­i­na­tion and ...

5 years ago
Pharma

The IBD mar­ket is set to soar to $32B. Ab­b­Vie could be the big win­ner, but there's meat left on the bone — top ...

5 years ago
Pharma

No­var­tis dives even deep­er in­to ra­di­oli­gands, notch­ing li­cens­ing deal with iTher­a­nos­tics for mul­ti­ple com­pounds

5 years ago
Deals

BioN­Tech makes a splash with $10B+ pro­jec­tion for 2021 Covid-19 vac­cine sales

5 years ago
Coronavirus

Go­ing head-to-head with Mer­ck on I/O, Genen­tech vets raise fresh round and en­ter clin­ic

5 years ago
Financing

Af­ter pi­lot project, Take­da inks $500M pact to tap in­to a Ke­van Shokat pro­tégé's co­va­lent small mol­e­cule fish­ing ...

5 years ago
Deals

Covid-19 roundup: CDC study con­firms re­al-world ef­fi­ca­cy of mR­NA shots; In­dia ex­port lim­its de­lay CO­V­AX ship­ments

5 years ago
Coronavirus

Flag­ship start­up Omega takes lead 'epige­nom­ic con­troller' can­di­date clos­er to the clin­ic with new $126M round

5 years ago
Financing

Af­ter tack­ling Covid-19 with As­traZeneca, Ox­ford's Jen­ner In­sti­tute is hard at work on a dif­fer­ent kind of vac­cine

5 years ago
Financing

FDA busts Mer­ck­'s Keytru­da in triple-neg­a­tive breast can­cer with a CRL — not un­ex­pect­ed giv­en its dis­as­trous ad­comm

5 years ago
Pharma
FDA+

Wave crash­es — again — as 2 more drugs go down to de­feat, this time for Hunt­ing­ton's

5 years ago
R&D

No­var­tis and Genen­tech push for clar­i­ty from FDA on how dis­ease pro­gres­sion mod­els can be used for reg­u­la­to­ry ...

5 years ago
Pharma
FDA+
First page Previous page 724725726727728729730 Next page Last page
A service from the Financial Times